The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down LSI Asia ‘25 in Singapore and gear up for LSI Europe ‘25 in London (September 7-11).

Accelus

Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants.

Aortyx

Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years.

Atraverse Medical

Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTWIRE™, its FDA-cleared transseptal access system. The funding will accelerate manufacturing, team expansion, and new product development, positioning Atraverse Medical to establish HOTWIRE as the next standard in left-heart access.

Augmedit

Announced the first closing of its Series A round to accelerate the global rollout of AI-driven augmented reality surgical software. Led by Egeria Impact Investments with participation from the EIC Fund, the raise supports commercialization in neurosurgery and expansion into new clinical specialties and markets.

Cognito Therapeutics

Reported positive results from the OVERTURE feasibility trial, demonstrating that Spectris AD significantly slows Alzheimer’s progression. The noninvasive neuromodulation therapy, which delivers gamma frequency light and sound, preserved cognitive function, daily activity, and brain volume in patients with mild-to-moderate Alzheimer’s disease.

Dilon Technologies

Received $9M in growth capital financing from JGB Management Inc. to accelerate operational scale-up and support continued double-digit revenue growth. The funding strengthens Dilon Technologies’ commercialization of its surgical portfolio, including HEMOBLAST BellowsⓇ, MarginProbeⓇ, and Navigator™ Gamma Probe product line.

GT Medical Technologies

Appointed James Leech as Chief Financial and Strategy Officer to accelerate corporate growth and expand adoption of GammaTileⓇ. Leech brings over a decade of life sciences leadership experience spanning medtech, healthcare services, and biopharma, with a focus on financial strategy, commercialization, and global operations.

iotaMotion

Secured U.S. Patent No. 12,311,173 and two NIH Phase I grants to expand robotic-assisted cochlear implant innovation. The milestones strengthen iotaMotion’s IP portfolio and support continued development of navigation-guided insertion and shape-changing polymer technologies.

Lungpacer Medical

Reported positive results from the 223-patient RESCUE3 RCT evaluating AeroPaceⓇ diaphragm neurostimulation technology. The study demonstrated significantly improved weaning success, reduced ventilator duration, fewer reintubations, and increased diaphragm strength.

Neurent Medical

Received FDA 510(k) clearance for its next-generation NEUROMARKⓇ System for chronic rhinitis. The updated platform introduces real-time feedback and enhanced control for ENT specialists, advancing Neurent Medical’s mission to deliver non-surgical relief from persistent nasal inflammation.

Nurami Medical

Completed its Series B financing to support continued growth and innovation in soft tissue repair. The round was led by a new strategic investor and the EIC Fund, with participation from existing investors backing Nurami’s proprietary electrospun biomaterial platform and flagship product, ArtiFasciaⓇ.

Positrigo

Closed an oversubscribed CHF 7M financing round to accelerate production and commercialization of the NeuroLF PET brain imaging system. The round was led by HealthCap and Navivo, with new board members bringing deep medtech, diagnostics, and commercial expertise to support Positrigo’s next phase of growth.

SPDx

Was acquired by Instrumentum, expanding its national footprint in surgical instrument sterilization services. The transaction marks a successful exit for cultivate(MD) and validates SPDx’s scalable off-site sterile processing model for hospitals and ASCs.

SurgiBox

Received two U.S. patents for its ultraportable operating field, strengthening SurgiBox’s IP portfolio as the company prepares for its next funding round. The patents include: 1) Data Analytics and Interface Platform for Portable Surgical Enclosure and 2) Systems and Methods for Using Blockchain to Secure Data Acquired in Surgical and Other Medical Procedures.

TYBR Health

Received FDA 510(k) clearance for the B3 GEL™ System, a bioresorbable gel designed to protect healing tissue and preserve mobility after surgery involving tendons, ligaments, and skeletal muscle. The clearance supports TYBR Health’s mission to improve surgical recovery and enables commercial launch later this year.

URO-1

Announced new equity financing, expanded manufacturing, and clinical validation of its SUREcoreⓇ biopsy needle and coreCAREⓇ tissue handling platform. The company’s platform has shown improved specimen quality, diagnostic accuracy, and reduced re-biopsy rates, advancing its mission to modernize prostate and soft tissue cancer diagnostics.

VenstraMedical

Achieved a 20-day duration in bench testing and a successful multi-day endpoint in an initial chronic animal model for its novel pVAD system. These results demonstrate promising durability, strong hydraulic performance, and low blood trauma as Venstra advances its next-generation therapy for cardiogenic shock.

Veyond Metaverse

Received Digital Health Canada’s 2025 Start-up Innovator of the Year award for its AI-powered 5D XR platform. The recognition highlights Veyond Metaverse’s impact in expanding access to expert care through real-time immersive applications in surgery, aviation, maritime, and military medicine.

Volta Medical

Received U.S. label expansion for Volta AF-Xplorer™ to include pivotal TAILORED-AF trial data. The update marks the first-ever level 1 evidence of improved efficacy in persistent atrial fibrillation using an AI-guided ablation strategy.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.